Back

HS3ST1 regulates pulmonary inflammation and is a determinant of clinical outcomes after trauma and hemorrhagic shock

Mokhtari, A. K.; Cotton, M. E.; Thomas, K. A.; Chitrakar, A.; Krocker, J. D.; Pokharel, M.; Osborn, B. K.; Huby Viduarre, M. d. P.; Mankame, A. R.; Wade, C. E.; Wang, Y.-W.; Orlicky, D. J.; Cohen, M. J.; Richter, J. R.; Shworak, N. W.; Cardenas, J.

2026-05-12 cell biology
10.64898/2026.05.07.723543 bioRxiv
Show abstract

Mechanisms that promote organ injury after trauma and hemorrhagic shock (T/HS) remain poorly defined. Endothelial heparan sulfates with a 3-O-sulfate (3-OS) modification, controlled by the HS3ST1 gene, have anticoagulant and anti-inflammatory properties through their interaction with antithrombin. Our objective was to determine whether HS3ST1 deficiency drives organ injury and poor outcomes after T/HS. Hs3st1-/- and wild-type (WT) mice were subjected to T/HS followed by resuscitation with lactated ringers (LR) or fresh frozen plasma (FFP). While no differences were observed between WT and Hs3st1-/- LR resuscitated mice, lung injury and leukocyte infiltrates were significantly increased in FFP resuscitated Hs3st1-/-compared to WT mice. In vitro, leukocyte slow rolling and adherence was increased in HS3ST1 KO compared to WT cells. Among 472 T/HS patients, of which 31 (7%) were homozygous for the rs16881446 variant allele (GG), the number of ventilator free days was lower, and mortality was significantly higher in AG and GG patients. The rs16881446 genotype was independently associated with mortality. In conclusion, HS3ST1 deficiency mitigates organ protection from FFP resuscitation, partly through mediating EC:leukocyte engagement, and predicts mortality after T/HS. These findings identify a novel therapeutic target and prognostic tool that can be leveraged towards improved risk stratification after trauma.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.1%
23.4%
2
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 0.2%
10.5%
3
Cell Death & Disease
126 papers in training set
Top 0.1%
6.6%
4
The American Journal of Pathology
31 papers in training set
Top 0.1%
3.7%
5
Journal of the American Heart Association
119 papers in training set
Top 2%
3.7%
6
PLOS ONE
4510 papers in training set
Top 42%
3.0%
50% of probability mass above
7
Frontiers in Immunology
586 papers in training set
Top 3%
2.7%
8
Blood
67 papers in training set
Top 0.6%
2.7%
9
JCI Insight
241 papers in training set
Top 2%
2.2%
10
Scientific Reports
3102 papers in training set
Top 55%
1.8%
11
eLife
5422 papers in training set
Top 40%
1.8%
12
Clinical and Translational Medicine
30 papers in training set
Top 0.5%
1.3%
13
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 6%
1.3%
14
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.2%
15
Function
15 papers in training set
Top 0.3%
1.0%
16
International Immunopharmacology
15 papers in training set
Top 0.3%
1.0%
17
Redox Biology
64 papers in training set
Top 0.6%
1.0%
18
Journal of Clinical Investigation
164 papers in training set
Top 5%
1.0%
19
Blood Advances
54 papers in training set
Top 1%
0.9%
20
The FASEB Journal
175 papers in training set
Top 2%
0.9%
21
Nature Communications
4913 papers in training set
Top 61%
0.8%
22
Cell Death Discovery
51 papers in training set
Top 1%
0.8%
23
British Journal of Haematology
15 papers in training set
Top 0.4%
0.8%
24
The Journal of Infectious Diseases
182 papers in training set
Top 4%
0.8%
25
Theranostics
33 papers in training set
Top 1%
0.8%
26
Cell Reports
1338 papers in training set
Top 32%
0.8%
27
EBioMedicine
39 papers in training set
Top 1.0%
0.8%
28
The Journal of Immunology
146 papers in training set
Top 1%
0.8%
29
Modern Pathology
21 papers in training set
Top 0.5%
0.7%
30
Arthritis & Rheumatology
33 papers in training set
Top 0.5%
0.7%